Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 6/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.44 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20531615 | 0.79 | CHRM5 (0.42) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL28497595 | 0.77 | CHRM5 (0.41) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL17832879 | 0.75 | LMNA (0.46) | SMN1; SMN2ADRA1ALMNABLMMAPK1 | |
| SCHEMBL28506563 | 0.75 | CYP2C19 (0.41) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL21549483 | 0.75 | CHRM5 (0.39) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL28464604 | 0.75 | CHRM5 (0.43) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL3118709 | 0.75 | CHRM5 (0.39) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL27883926 | 0.75 | CHRM5 (0.39) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL4271128 | 0.75 | CHRM5 (0.45) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL8910739 | 0.75 | CHRM1 (0.45) | CHRM5CHRM1CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503800-B1 | TREATMENT AND PREVENTION OF TISSUE DAMAGE ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN PRODUCTION | PENTRAXIN THERAPEUTICS LTD (GB) | 2009-10-28 | — | — | EP | claimed |
| US-20060019930-A1 | Treatment and prevention of tissue damage | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | US | claimed |
| EP-0518959-B1 | METHOD OF IMPROVING THE OCULAR HAEMO AND BIOCOMPATIBILITY OF SYNTHETIC POLYMERS | BIOCOMPATIBLES LTD (GB) | 1996-11-20 | — | — | EP | claimed |
| CN-107920504-B | Choline salts and ammonium-free adjuvants for water conditioning and agricultural formulations | 罗地亚经营管理公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230118142-A1 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | UCL BUSINESS LTD (GB) | 2023-04-20 | — | — | US | disclosed |
| CN-109248671-A | A kind of preparation method and applications of the silica surface based on the modification of cyclic phosphate choline polymer | 天津大学 | 2019-01-22 | — | — | CN | disclosed |
| US-9943624-B2 | Multi-functional surface coating of implants | UNIVERSITY OF MASSACHUSETTS (US) | 2018-04-17 | — | — | US | disclosed |
| EP-2770328-B1 | Method to diagnose pancreatic cancer | PHENOMENOME DISCOVERIES INC (CA) | 2017-12-27 | — | — | EP | disclosed |
| EP-3124980-A1 | MASS SPECTROPHOTOMETRIC METHOD TO DIAGNOSE PANCREATIC CANCER | Phenomenome Discoveries Inc. (CA) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015193504-A1 | SEPARATION MATERIAL COMPRISING PHOSPHORYL CHOLINE DERIVATIVES | PENTRACOR GMBH (DE) | 2015-12-23 | — | — | WO | disclosed |
| US-8668919-B2 | Polymer for creating hemocompatible surface | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-03-11 | — | — | US | disclosed |
| EP-1974914-A2 | Lithographic printing plate precursor and method of preparing lithographic printing plate | FUJIFILM Corporation (JP) | 2008-10-01 | — | — | EP | disclosed |
| CN-1332038-C | Method of judging mismatch between single-stranded nucleic acid molecules | NOF CORP (JP) | 2007-08-15 | — | — | CN | disclosed |
| US-20060019930-A1 | Treatment and prevention of tissue damage | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | US | disclosed |
| CN-1547616-A | Method for determining mismatch between single-stranded nucleic acid molecules | 日本油脂株式会社 | 2004-11-17 | — | — | CN | disclosed |
| US-5591882-A | Process for preparing organophosphates useful for increasing the ocular haemo- and biocompatibility of synthetic polymers | BIOCOMPATIBLES LIMITED (GB) | 1997-01-07 | — | — | US | disclosed |
| EP-0518959-B1 | METHOD OF IMPROVING THE OCULAR HAEMO AND BIOCOMPATIBILITY OF SYNTHETIC POLYMERS | BIOCOMPATIBLES LTD (GB) | 1996-11-20 | — | — | EP | disclosed |
| US-5422402-A | Surface treatment (of an acrylic, polypropylene, polyethylene, polyurethane, polysaccharide, or cellulosic material) with quaternary ammonium phosphate inner salt having a reactive functional group; contact lenses; blood filtration | BIOCOMPATIBLES LIMITED (GB) | 1995-06-06 | — | — | US | disclosed |
| EP-0518959-A1 | METHOD OF IMPROVING THE OCULAR HAEMO AND BIOCOMPATIBILITY OF SYNTHETIC POLYMERS. | BIOCOMPATIBLES LTD (GB) | 1992-12-23 | — | — | EP | disclosed |
| WO-1991013639-A1 | METHOD OF IMPROVING THE OCULAR HAEMO AND BIOCOMPATIBILITY OF SYNTHETIC POLYMERS | BIOCOMPATIBLES LIMITED (GB) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019930-A1 | Treatment and prevention of tissue damage | TTR, RBP1, SERPINA6 | CHRM5 1520/4885CHRM1 1154/4885CHRM3 892/4885 |
| US-20230118142-A1 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | LPO, AOX1, MPO | CHRM5 2311/4885CHRM1 874/4885CHRM3 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.